Legal & General Group
HARP

Legal & General Group’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Legal & General Group’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-198
Closed -$10K – 3720
2022
Q1 		$10K Hold
198
– – ﹤0.01% 3413
2021
Q4 		$15K Hold
198
– – ﹤0.01% 3370
2021
Q3 		$16K Hold
198
– – ﹤0.01% 3354
2021
Q2 		$27K Buy
198
+51
+35% +$9.73K ﹤0.01% 3184
2021
Q1 		$31K Buy
147
+14
+11% +$2.81K ﹤0.01% 2985
2020
Q4 		$22K Hold
133
– – ﹤0.01% 3062
2020
Q3 		$23K Sell
133
-41
-24% -$5.91K ﹤0.01% 2940
2020
Q2 		$29K Buy
174
+63
+57% +$9.83K ﹤0.01% 2917
2020
Q1 		$13K Sell
111
-21
-16% -$2.95K ﹤0.01% 3103
2019
Q4 		$21K Buy
132
+12
+10% +$1.82K ﹤0.01% 3173
2019
Q3 		$16K Buy
120
+52
+76% +$7.31K ﹤0.01% 3196
2019
Q2 		$8K Hold
68
– – ﹤0.01% 3401
2019
Q1 		$6K Buy
+68
New +$8.94K ﹤0.01% 3304

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Legal & General Group's HARP Position: Q2 2022 in Review

Legal & General Group sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2022, closing a stake of 198 shares — an estimated $10K sold.

Legal & General Group first reported a position in HARP in Q1 2019 and held it in 13 quarters. The position peaked at $31K in Q1 2021. 63 funds tracked by Wall St. Rank hold HARP as of Q2 2022.

  • Legal & General Group reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 198 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $10K.
  • Legal & General Group first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • Legal & General Group's Harpoon Therapeutics, Inc. Common Stock position peaked at $31K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.